Pharming Group NV ADR Dossier - Source-backed chat

Pharming Group NV ADR

PHARMEuronext Amsterdam

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.38

Intrinsic Value $8.90median of 4 methods · middle span $7-$11based on filings through 31 Dec 2025

Market Price $9.95Price as of 1 Oct 2026

Near fair valueIntrinsic value is 11% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $704.2M

Enterprise Value $651.7M

Moat Rating Narrow

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Pharming Group N.V. has transitioned from a speculative, single-product biotech into a fundamentally attractive, cash-generating rare disease company. The company's growth is driven by its legacy HAE franchise, RUCONEST, which provides stable cash flows, and the rapid commercial expansion of Joenja (leniolisib) for APDS. Despite seasonal variability and competitive headwinds in Q1 2026, Pharming's self-sustaining business model, robust gross margins (~88%), and strong cash position enable it to fund its clinical pipeline independently. Key near-term catalysts, including the upcoming FDA PDUFA date for Joenja's pediatric label expansion in October 2026 and launches in Japan and Europe, position the company for significant long-term valuation upside.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$23.40

Mean target$34.35

High · most bullish analyst$39.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects prolonged competitive pressure on RUCONEST from novel HAE therapies, leading to steeper-than-anticipated revenue declines. Additionally, regulatory delays or another Complete Response Letter (CRL) for Joenja's pediatric expansion or international launches could stall growth. Higher-than-expected R&D and commercialization expenses could strain cash flows, forcing the company to seek external financing under less favorable market conditions.

Base CaseCentral scenario

The base case assumes Pharming successfully navigates the competitive HAE landscape, maintaining RUCONEST as a highly sticky, cash-generating cornerstone. Joenja continues its strong commercial trajectory in the US and successfully launches in Japan and Europe following recent regulatory milestones. The FDA approves the pediatric sNDA for Joenja by the October 2026 PDUFA date, unlocking a key patient demographic. Operating expenses remain disciplined within the guided $330M to $335M range, allowing the company to achieve sustained profitability and fund its pipeline without dilutive capital raises.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Transition to a self-sustaining, cash-generating business model with $376M in FY2025 revenue and positive operating cash flows.
Strong commercial execution of Joenja (leniolisib), delivering 34% YoY growth in Q1 2026 and expanding globally.
High gross margins (~88%) typical of specialized rare disease therapies, supporting robust profitability potential.
Sticky patient base for RUCONEST due to high efficacy and a transgenic manufacturing platform that acts as a barrier to biosimilar entry.

Key Investment Risks

Intensifying competition in the hereditary angioedema (HAE) market impacting RUCONEST sales.
Regulatory risks, including potential delays or non-approval of Joenja's pediatric label expansion by the FDA.
Revenue variability and seasonality, as demonstrated by the sequential decline in Q1 2026.
Material weaknesses in internal controls over financial reporting disclosed during the auditor transition.

Thesis Invalidation Triggers

A second FDA rejection or significant delay of the Joenja pediatric sNDA beyond late 2026.
RUCONEST revenue declining by more than 20% annually, severely impacting the company's self-funding capacity.
Failure to launch Joenja successfully in Japan and Europe in 2026.
Operating expenses significantly exceeding guidance without a corresponding increase in top-line revenue.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.